公开(公告)号：US20170145114A1

公开(公告)日：2017-05-25

申请号：US15417973

申请日：2017-01-27

Applicant: UCB BIOPHARMA SPRL

Inventor： Andrew George POPPLEWELL ,  Simon Peter TICKLE ,  Heather Margaret LADYMAN

IPC: C07K16/46 ,  C07K16/30 ,  C07K16/28

CPC classification number: C07K16/464 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2803 ,  C07K16/2851 ,  C07K16/3061 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.

公开(公告)号：US20170029495A1

公开(公告)日：2017-02-02

申请号：US15297055

申请日：2016-10-18

Applicant: AbbVie Inc.

Inventor： Christopher M. CHUMSAE

IPC: C07K16/24 ,  G01N30/96 ,  B01D15/36

CPC classification number: C07K16/241 ,  B01D15/362 ,  C07K1/18 ,  C07K2317/21 ,  C07K2317/40 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N30/96

Abstract: Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MGO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.

Abstract translation: 鉴定了甲基乙二醛（MGO）修饰的重组TNF-α抗体（例如阿达木单抗）。 MGO修饰降低阿达木单抗与TNF-α之间的结合。 公开了用于在产生阿达木单抗TNF-α抗体中减少MGO修饰的抗体的存在的方法。

公开(公告)号：US20170028081A1

公开(公告)日：2017-02-02

申请号：US15267910

申请日：2016-09-16

Applicant: Immunomedics, Inc.

Inventor： Serengulam V. Govindan ,  Sung-Ju Moon ,  David M. Goldenberg

IPC: A61K47/48 ,  C07K16/30 ,  C07K16/10 ,  A61K31/4745

CPC classification number: A61K47/6803 ,  A61K31/4745 ,  A61K45/06 ,  A61K47/6841 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6853 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6861 ,  A61K47/6889 ,  A61K2039/505 ,  A61N5/10 ,  C07D491/22 ,  C07K16/1063 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/303 ,  C07K16/3046 ,  C07K16/3076 ,  C07K16/3092 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/94 ,  Y02A50/394 ,  Y02A50/401 ,  Y02A50/403 ,  Y02A50/412 ,  Y02A50/473 ,  Y02A50/478

Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.

Abstract translation: 本发明涉及具有改善靶向各种含有靶向部分（例如抗体或抗体片段）的病变细胞，接头和治疗部分的能力的治疗性缀合物，还涉及制备和使用缀合物的方法。

公开(公告)号：US09505833B2

公开(公告)日：2016-11-29

申请号：US14078181

申请日：2013-11-12

Applicant: ABBVIE INC.

Inventor： Christopher M. Chumsae

IPC: C07K16/24 ,  C07K1/18

CPC classification number: C07K16/241 ,  B01D15/362 ,  C07K1/18 ,  C07K2317/21 ,  C07K2317/40 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N30/96

Abstract: Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MOO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.

Abstract translation: 鉴定了甲基乙二醛（MGO）修饰的重组TNF-α抗体（例如阿达木单抗）。 MGO修饰降低阿达木单抗与TNF-α之间的结合。 公开了用于在产生阿达木单抗TNF-α抗体中减少MOO-修饰的抗体的存在的方法。

公开(公告)号：US20160331842A1

公开(公告)日：2016-11-17

申请号：US15214331

申请日：2016-07-19

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Delphine Bregeon ,  Patrick Dennler ,  Christian Belmant ,  Laurent Gauthier ,  François Romagne ,  Eliane Fischer ,  Roger Schibli

IPC: A61K47/48 ,  C07K16/30 ,  A61K31/5517

CPC classification number: A61K47/48569 ,  A61K31/5517 ,  A61K47/6801 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6889 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/40

Abstract: The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

公开(公告)号：US09435809B2

公开(公告)日：2016-09-06

申请号：US14232801

申请日：2012-07-13

Applicant: Stephen D. Nimer ,  Lan Wang

Inventor： Stephen D. Nimer ,  Lan Wang

IPC: C12Q1/00 ,  C12N15/01 ,  G01N33/574 ,  G01N33/50 ,  C07K16/44 ,  C12N15/113 ,  C12Q1/68

CPC classification number: G01N33/57426 ,  C07K16/18 ,  C07K16/44 ,  C07K2317/34 ,  C07K2317/40 ,  C12N15/1135 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N2333/47 ,  G01N2440/10 ,  G01N2500/00 ,  G01N2500/04

Abstract: The present invention relates to methods and compositions for treating and reducing the risk of Acute Myelogenous Leukemia (AML). In particular, the invention provides methods for identifying novel treatments for AML based on reproducible and detectable changes in AML1-ETO acetylation. The present invention further provides methods of using these treatments.

Abstract translation: 本发明涉及治疗和降低急性骨髓性白血病（AML）风险的方法和组合物。 特别地，本发明提供了基于AML1-ETO乙酰化可重复和可检测的变化来鉴定AML的新治疗的方法。 本发明还提供了使用这些处理的方法。

公开(公告)号：US20160251336A1

公开(公告)日：2016-09-01

申请号：US15028005

申请日：2014-10-10

Applicant: SUTRO BIOPHARMA, INC.

Inventor： Wenjin YANG ,  Qun YIN

IPC: C07D401/12 ,  A61K47/48 ,  C12P21/00 ,  C07K16/28 ,  C12N9/00 ,  C07K5/078 ,  C07K16/40

CPC classification number: C07D401/12 ,  A61K47/60 ,  A61K47/64 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6871 ,  C07D257/08 ,  C07D409/12 ,  C07K5/06139 ,  C07K16/22 ,  C07K16/28 ,  C07K16/2833 ,  C07K16/2878 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/50 ,  C07K2317/526 ,  C07K2317/567 ,  C07K2317/76 ,  C12N9/93 ,  C12P21/00 ,  C12P21/02 ,  C12Y601/01001

Abstract: Provided herein are modified amino acids comprising a tetrazine groups according to Formula I: polypeptides, antibodies, payloads and conjugates comprising these modified amino acid residues derived from the modified amino acids, and methods of producing the polypeptides, antibodies, payloads and conjugates comprising the modified amino acid residues. The polypeptides, antibodies, payloads and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract translation: 本文提供了包含根据式I的四嗪基的修饰的氨基酸：包含衍生自经修饰的氨基酸的这些修饰的氨基酸残基的多肽，抗体，有效载荷和缀合物，以及产生多肽，抗体，有效载荷和缀合物的方法， 氨基酸残基。 多肽，抗体，有效载荷和缀合物可用于治疗和预防的方法，检测方法和诊断方法。

公开(公告)号：US20160222130A1

公开(公告)日：2016-08-04

申请号：US15134803

申请日：2016-04-21

Applicant: Astellas Pharma Inc.

Inventor： Masazumi Kamohara ,  Shigenori Yagi ,  Yoshinori Ishii ,  Hiromi Nara

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A61K39/395 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/40 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/64 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C12N5/06 ,  C12N15/09 ,  C12N15/63 ,  C12N2510/02

Abstract: Provided is an anti-human Tie2 antibody for preventing or treating diabetic macular edema, diabetic retinopathy, and critical limb ischemia by binding to a human Tie2 to activate the human Tie2. The present inventors have conducted investigations on an anti-human Tie2 antibody, and have thus provided an anti-human Tie2 antibody comprising four heavy chain variable regions and four light chain variable regions, in which the heavy chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 122 of SEQ ID NO: 2, the light chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 113 of SEQ ID NO: 4, the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody comprises four antigen-binding sites.

Abstract translation: 提供一种抗人Tie2抗体，通过结合人Tie2来激活人类Tie2，预防或治疗糖尿病性黄斑水肿，糖尿病性视网膜病变和严重肢体缺血。 本发明人对抗人Tie2抗体进行了研究，因此提供了包含四个重链可变区和四个轻链可变区的抗人Tie2抗体，其中重链可变区由氨基酸序列 的SEQ ID NO：2的氨基酸编号1〜122，轻链可变区由SEQ ID NO：4的氨基酸编号1〜113的氨基酸序列，1个重链可变区和1个重链可变区 轻链可变区构成一个抗原结合位点，抗体包含四个抗原结合位点。

公开(公告)号：US20160200823A1

公开(公告)日：2016-07-14

申请号：US15084088

申请日：2016-03-29

Applicant: UCB PHARMA S.A. ,  BIOGEN IDEC MA INC.

Inventor： LINDA C. BURKLY ,  JANINE L. FERRANT-ORGETTAS ,  ELLEN A. GARBER ,  YEN-MING HSU ,  LIHE SU ,  FREDERICK R. TAYLOR ,  RALPH ADAMS ,  DEREK THOMAS BROWN ,  ANDREW GEORGE POPPLEWELL ,  MARTYN KIM ROBINSON ,  ANTHONY SHOCK ,  KERRY LOUISE TYSON

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

公开(公告)号：US20160194391A1

公开(公告)日：2016-07-07

申请号：US14886978

申请日：2015-10-19

Applicant: MEDIMMUNE LIMITED

Inventor： Kenneth Grabstein ,  William Brady ,  Gordon King ,  Natalie Winblade Nairn ,  Kurt David Shanebeck ,  Paul Heffner Slagle ,  Kenneth Christopher Thornton ,  Michael Peter Vanbrunt ,  Andrea Wang ,  Hengyu Xu

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/248 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/40 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates inter alia to a bivalent, bispecific construct comprising an anti-IL-6 antibody, or derivative thereof, and an anti-IL-23 antibody, or derivative thereof and its use in therapy. The invention also relates to useful anti-IL-6 and anti-IL-23 antibodies.

Abstract translation: 本发明特别涉及包含抗IL-6抗体或其衍生物和抗IL-23抗体或其衍生物的二价双特异性构建体及其在治疗中的用途。 本发明还涉及有用的抗IL-6和抗IL-23抗体。